At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 63 enrolled
Drug / intervention
pegfilgrastim +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose-Escalation Study of LY2523355 in Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating pegfilgrastim and LY2523355 for Advanced Cancer. Completed, enrolled 63 participants across 2 sites.
Detailed Summary
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedOct 2010
Primary CompletionDec 2011
Study CompletionJun 2012
TodayJul 2026
First PostedOct 5, 2010
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.7 years ago
Interventions
pegfilgrastimdrug
Administered subcutaneously
LY2523355drug
Administered intravenously